Eli Lilly is making a major push into infectious disease prevention with the planned acquisition of three vaccine developers. The pharma giant will pay up to $1.55 billion for Vaccine Company, up to $1.5 billion for Curevo, and up to $780 million for LimmaTech Biologics, totaling as much as $3.8 billion in potential deal value.
The acquisitions target a range of pathogens through differentiated technology platforms. Lilly aims to focus on viral pathogens associated with long-term neurological and oncological risks, as well as bacterial pathogens historically considered difficult to prevent or treat. The move marks a significant expansion beyond Lilly's core therapeutic areas.
Each company brings distinct vaccine approaches: Vaccine Company focuses on novel viral targets, Curevo specializes in adjuvanted vaccines, and LimmaTech develops vaccines against bacterial threats. The combined platforms could accelerate development of shots against diseases like shingles, Lyme disease, and certain cancer-linked viruses.
Financial terms include upfront and milestone payments. The deals are expected to close in the coming months pending regulatory approvals. Lilly did not provide specific timelines for clinical development or potential market launches of any candidate vaccines.
The strategy positions Lilly in a competitive vaccine market dominated by Merck, Pfizer, and GSK. However, vaccine development carries high risk—many candidates fail in trials, and the $3.8 billion price tag depends on achieving all milestones. Success hinges on whether the early-stage platforms can yield approved products.